{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.1","upperLimit":"4.4","value":"3.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"36"}],"units":"Participants"}],"description":"Progression free survival is defined as time from treatment start date to date of progression or death from any cause, whichever occurs first. Disease progression was evaluated using the Response Evaluation Criteria in Solid Tumors version 1.1, the Cheson (2014) criteria for lymphoma patients, and the Response Assessment in Neuro-Oncology criteria for glioblastoma patients. Median PFS will be estimated using the Kaplan-Meier method.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive trastuzumab emtansine IV over 30-90 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.\n\nTrastuzumab Emtansine: Given IV","id":"OG000","title":"Treatment (Trastuzumab Emtansine)"}],"paramType":"MEDIAN","populationDescription":"Patients who were eligible and received protocol treatment","reportingStatus":"POSTED","timeFrame":"Assessed at baseline, then every 3 cycles for the first 33 cycles and every 4 cycles thereafter until disease progression, up to 3 years post registration","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}